Depression during the COVID-19 pandemic (analysis of clinical cases)
https://doi.org/10.14412/2074-2711-2021-1-81-86
Abstract
Currently, in various world regions, the prevalence of depressive and anxiety disorders due to the impact of coronavirus infection is repeatedly increased compared to that in previous years. Among the predictors of their development during the pandemic, there are COVID-19 symptoms, a history of mental disorders, as well as restrictive measures, and financial losses.
The paper describes three clinical cases of depressive disorders during the COVID-19 pandemic, with the depiction of the anamnesis, somatic and mental status, the patholopsychogical qualification of the condition, and the justification of a therapy regimen. The multifactorial stressor effect of the COVID-19 pandemic has provoked an exacerbation of depression in a male patient with a history of affective disorder; the development of a nosogenic depressive reaction of demoralization in a female patient with coronavirus pneumonia; the worsening of somatization dysthymia in a female patient of involutional age. The timely recognition of depression and its treatment with currently available antidepressants have contributed to the achievement of high-quality remission, the increase of stress resistance, and the improvement of quality of life in the patients.
Supporting agencies: This article has been supported by Sotex PharmFirma. The sponsor has participated in the development of the investigation project and supported the investigation program, as well as in the decision to submit the article for publication.
About the Author
I. Yu. Dorozhenok
I.M. Sechenov First Moscow Medical University (Sechenov University), Ministry of Health of Russia; Mental Health Research Center
Russian Federation
Russian Federation
Igor Yuryevich Dorozhenok
8, Trubetskaya St., Build. 2, Moscow 119991
34, Kashirskoe Shosse, Moscow 115522
References
1. McCracken LM, Badinlou F, Buhrman M, Brocki KC. Psychological impact of COVID-19 in the Swedish population: Depression, anxiety, and insomnia and their associations to risk and vulnerability factors. Eur Psychiatry. 2020 Aug 26;63(1):e81. doi: 10.1192/j.eurpsy.2020.81
2. Shi L, Lu ZA, Que JY, et al. Prevalence of and Risk Factors Associated With Mental Health Symptoms Among the General Population in China During the Coronavirus Disease 2019 Pandemic. JAMA Netw Open. 2020 Jul 1;3(7):e2014053. doi: 10.1001/jamanetworkopen.2020.14053
3. Asmundson GJG, Paluszek MM, Landry CA, et al. Do pre-existing anxiety-related and mood disorders differentially impact COVID-19 stress responses and coping? J Anxiety Disord. 2020 Aug;74:102271. doi: 10.1016/j.janxdis.2020.102271. Epub 2020 Jul 7.
4. Iob E, Frank Ph, Steptoe A, Fancourt D. Levels of Severity of Depressive Symptoms Among At-Risk Groups in the UK During the COVID-19 Pandemic. JAMA Netw Open. 2020 Oct;3(10):e2026064. doi: 10.1001/jamanetworkopen.2020.26064
5. Van Rheenen TE, Meyer D, Neill E, et al. Mental health status of individuals with a mood-disorder during the COVID-19 pandemic in Australia: Initial results from the COLLATE project. J Affect Disord. 2020 Oct 1;275:69-77. doi: 10.1016/j.jad.2020.06.037. Epub 2020 Jul 2.
6. Hao F, Tan W, Jiang L, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun. 2020 Jul;87:100-6. doi: 10.1016/j.bbi.2020.04.069. Epub 2020 Apr 27.
7. Bo HX, Li W, Yang Y, et al. Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychol Med. 2020. doi: 10.1017/S0033291720000999. Epub. 2020 Mar 27.
8. Liu D, Baumeister RF, Veilleux JC, et al. Risk factors associated with mental illness in hospital discharged patients infected with COVID-19 in Wuhan, China. Psychiatry Res. 2020 Oct;292:113297. doi: 10.1016/j.psychres.2020.113297. Epub 2020 Jul 13.
9. Poyraz BC, Poyraz CA, Olgun Y, et al. Psychiatric morbidity and protracted symptoms after COVID-19. Psychiatry Res. 2020 Nov 28;295:113604. doi: 10.1016/j.psychres.2020.113604. Online ahead of print.
10. Mazza MG, De Lorenzo R, Conte C, et al; COVID-19 BioB Outpatient Clinic Study group; Benedetti F. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020 Oct;89:594-600. doi: 10.1016/j.bbi.2020.07.037. Epub 2020 Jul 30.
11. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020 Nov 12. doi: 10.1001/jama.2020.22760. Epub ahead of print.
12. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020 14-20 March;395(10227): 912-20. doi: 10.1016/S0140-6736(20)30460-8. Epub 2020 Feb 26.
13. Guo J, Feng XL, Wang XH, van IJzendoorn MH. Coping with COVID-19: Exposure to COVID-19 and Negative Impact on Livelihood Predict Elevated Mental Health Problems in Chinese Adults. Int J Environ Res Public Health. 2020 May 29;17(11):3857. doi: 10.3390/ijerph17113857
14. Chew NWS, Lee GKH, Tan BYQ, et al. A multinational, multicentre study on the psychological outcomes and associated physical symptoms amongst healthcare workers during COVID-19 outbreak. Brain Behav Immun. 2020 Aug;88:559-65. doi: 10.1016/j.bbi.2020.04.049. Epub 2020 Apr 21.
15. Al Omari O, Al Sabei S, Al Rawajfah O, et al. Prevalence and Predictors of Depression, Anxiety, and Stress among Youth at the Time of COVID-19: An Online Cross-Sectional Multicountry Study. Depress Res Treat. 2020 Oct 6;2020:8887727. doi: 10.1155/2020/8887727. eCollection 2020.
16. Kujawa A, Green H, Compas BE, et al. Exposure to COVID-19 pandemic stress: Associations with depression and anxiety in emerging adults in the United States. Depress Anxiety. 2020 Dec;37(12):1280-8. doi: 10.1002/da.23109. Epub 2020 Nov 10.
Review
For citations:
Dorozhenok IY. Depression during the COVID-19 pandemic (analysis of clinical cases). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):81-86. (In Russ.) https://doi.org/10.14412/2074-2711-2021-1-81-86
Views:
817
Email this article 